Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases
Status:
Terminated
Trial end date:
2019-08-09
Target enrollment:
Participant gender:
Summary
This is an open-label phase II clinical trial designed to allow a preliminary assessment of
the efficacy and safety of cabozantinib in unselected Non-Small Cell Lung Cancer (NSCLC)
patients with metastases to the brain and in the subset of patients with c-MET amplified
Non-Small Cell Lung Cancer with metastases to the brain. Previously treated patients with
non-squamous NSCLC who have had brain metastases at any point in their treatment history are
eligible for enrollment on this clinical trial. Patients with clinically asymptomatic
untreated brain metastases will be allowed on trial at the discretion of the treating
investigator. Patients who have undergone treatment for their brain metastases with
Whole-Brain Radiation Therapy (WBRT), stereotactic radiosurgery (SRS) or surgery must be
clinically stable and recovered from all procedures at the time of study enrollment.